Clinical trial
R115777 in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00005041 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00005041 |
|---|---|
| Title | R115777 in Treating Patients With Relapsed Small Cell Lung Cancer |
| Official title | A Phase II Study to Determine the Antitumor Activity of Farnesyltransferase Inhibitor R115777 in Subjects With Relapsed Small Cell Lung Cancer |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | tipifarnib |
| Start date | Sep 1, 1999 |
| Primary completion | May 1, 2000 |
| First posted | Jun 18, 2004 |
| Last update posted | Nov 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: